Product introduction :

CAS: 367514-88-3

Appearance: white to off-white powder.

MF: C28H36N4O2S

MW: 492.684

Mp: 243-248ºC

Assay: ≥99.0%

Lurasidone hydrochloride (CAS 367514-87-2) is a novel benzisothiazole derivative classified as an atypical antipsychotic, with the chemical name (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride. This white to off-white crystalline powder has a molecular weight of 529.09 g/mol (as hydrochloride salt) and demonstrates good solubility in water (>100 mg/mL) and organic solvents like . The compound exhibits a melting point range of 218-222°C (decomposition) and maintains stability under normal storage conditions (room temperature, protected from light and moisture). Analytical characterization by HPLC typically shows purity levels exceeding 99%, with major impurities including desbenzothiazole derivatives and oxidation byproducts. Lurasidone's unique molecular structure combines a benzisothiazole moiety with a cyclohexylhexahydro-isoindoledione group, contributing to its distinctive receptor binding profile. Pharmacokinetically, it demonstrates moderate oral bioavailability (9-19%) due to extensive first-pass metabolism, with peak plasma concentrations reached within 1-3 hours and an elimination half-life of approximately 18 hours. The drug undergoes hepatic metabolism primarily via CYP3A4, producing active metabolites that contribute to its therapeutic effects.
 

Application: Lurasidone hcl powder cas 367514-88-3 is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives. Lurasidone hcl powder cas 367514-88-3 (Latuda) belongs to a class of medications known as atypical antipsychotics. Other members of this class include clozapine (Clozaril), risperidone (Risperdal), aripiprazole (Abilify) and ziprasidone (Geodon). Atypical antipsychotics like lurasidone are considered the standard of care for treating schizophrenia. Additionally, in clinical studies lurasidone was shown to be effective in improving mood in many people struggling with bipolar depression. Lurasidone can be taken alone or with either lithium (Lithobid) or valproate (Depakote).

Lurasidone hcl powder cas 367514-88-3 was approved for the treatment of schizophrenia in adults in October, 2010. Almost three years later in July, 2012 the FDA approved lurasidone for the treatment of depressive episodes associated with bipolar I disorder.

Please send me inquiry for the full product list